Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving transferase
Reexamination Certificate
2006-07-06
2010-10-12
Prouty, Rebecca E. (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving transferase
C435S007240
Reexamination Certificate
active
07811781
ABSTRACT:
A method of indicating the presence of the atherosclerosis (particularly coronary artery atherosclerosis) in a subject is provided, comprising comparing the level of Core 2 GlcNAc-T in a tissue sample from a subject with a reference level determined for the same tissue. A level of Core 2 GlcNAc-T in the tissue sample from a subject that is higher than that of the reference level being indicative that the subject is afflicted with atherosclerosis (particularly coronary artery atherosclerosis—coronary artery disease—CAD). In preferred embodiments, the sample consists of leukocytes and the protein level is determined as the enzymatic activity using radiolabeled UDP-GlcNAc and a Galβ(1,3)-GalNAc derivative.
REFERENCES:
patent: 5104856 (1992-04-01), Esko et al.
patent: 5360733 (1994-11-01), Fukuda et al.
patent: 5461143 (1995-10-01), Wong et al.
patent: 5486510 (1996-01-01), Bouic et al.
patent: 5589182 (1996-12-01), Tashiro et al.
patent: 5624832 (1997-04-01), Fukuda et al.
patent: 5658778 (1997-08-01), Fukuda et al.
patent: 5843707 (1998-12-01), Larsen et al.
patent: 5880091 (1999-03-01), Cummings et al.
patent: 5886029 (1999-03-01), Dhaliwal
patent: 5952393 (1999-09-01), Sorkin, Jr.
patent: 5958770 (1999-09-01), Cham et al.
patent: 5965449 (1999-10-01), Novak
patent: 5985936 (1999-11-01), Novak
patent: 6042834 (2000-03-01), Baraka
patent: 6087353 (2000-07-01), Stewart et al.
patent: 6131578 (2000-10-01), King et al.
patent: 6197832 (2001-03-01), Sorkin, Jr.
patent: 6346267 (2002-02-01), Fry et al.
patent: 6383514 (2002-05-01), Weitkemper et al.
patent: 6407085 (2002-06-01), Kief
patent: 6635461 (2003-10-01), Schwientek et al.
patent: 6787151 (2004-09-01), Meijer et al.
patent: 6933291 (2005-08-01), Qi et al.
patent: 6998501 (2006-02-01), Wright et al.
patent: 2002/0018811 (2002-02-01), Penteado et al.
patent: 2002/0098563 (2002-07-01), Korczak et al.
patent: 2002/0156051 (2002-10-01), Kutney et al.
patent: 2002/0183294 (2002-12-01), Barraclough et al.
patent: 2002/0193317 (2002-12-01), Xia et al.
patent: 2003/0004147 (2003-01-01), Barraclough et al.
patent: 2003/0096316 (2003-05-01), Wester
patent: 2004/0033521 (2004-02-01), Korczak et al.
patent: 2004/0038923 (2004-02-01), Marth et al.
patent: 2004/0049352 (2004-03-01), Andre et al.
patent: 2004/0203111 (2004-10-01), Schwientek et al.
patent: 2004/0220115 (2004-11-01), Cham
patent: 2004/0249138 (2004-12-01), Lawson
patent: 2006/0052351 (2006-03-01), Platt et al.
patent: 2007/0254847 (2007-11-01), Liu et al.
patent: 2186987 (2000-06-01), None
patent: 2 335 436 (2001-08-01), None
patent: 1237583 (1999-12-01), None
patent: 1243129 (2000-02-01), None
patent: 1361111 (2002-07-01), None
patent: 1 316 608 (2003-06-01), None
patent: 0 850 243 (2003-10-01), None
patent: 1 800 685 (2007-06-01), None
patent: 2 027 434 (1995-01-01), None
patent: WO 97/06176 (1997-02-01), None
patent: WO 98/06405 (1998-02-01), None
patent: WO 99/39715 (1999-08-01), None
patent: WO 99/53925 (1999-10-01), None
patent: WO 00/31109 (2000-06-01), None
patent: WO 00/52029 (2000-09-01), None
patent: WO 00/78789 (2000-12-01), None
patent: WO 01/83717 (2001-11-01), None
patent: WO 02/24212 (2002-03-01), None
patent: WO 02/069980 (2002-09-01), None
patent: WO 02/087548 (2002-11-01), None
patent: WO 03/075931 (2003-09-01), None
patent: WO 2004/002497 (2004-01-01), None
patent: WO 2004/029068 (2004-04-01), None
patent: WO 2004/048938 (2004-06-01), None
patent: WO 2004/111196 (2004-12-01), None
Nielson, C and Lange, T. Blood Glucose and Heart Failure in Nondiabetic Patients; Diabetes Care, vol. 28, No. 3 (2005) pp. 607-611.
Nishio et al. Identification and Characterization of a Gene Regulating Enzymatic Glycosylation Which is Induced by Diabetes and Hyperglycemia Specifically in Rat Cardiac Tissue; Journal of Clinical Investigation, vol. 96 (1995) pp. 1759-1767.
Koya et al. Overexpression of Core 2 N-Acetylglycosaminyltransferase Enhances Cytokine Actions and Induces Hypertrophic Myocardium in Transgenic Mice; The FASEB Journal, vol. 13 (1999) pp. 2329-2337.
Chibber et al. Activity of the Glycosylating Enzyme, Core 2 GLCNAC (BETA1,6) Transferase, is Higher in Polymorphonuclear Leukocytes From Diabetic Patients Compared With Age-Matched Control Subjects; Diabetes, vol. 49 (2000) pp. 1724-1730.
Notification Concerning Transmittal of International Preliminary Report on patentability; Int'l Application No. PCT/GB2006/002502; Int'l Filing Date Jul. 6, 2006, mailed Jan. 17, 2008 (9 pgs).
Battistini, L. et al; “CD8+T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1”,Blood, vol. 101 No. 12, 4775-4780 (2003).
Ben-Mahmud, Bahaedin M., et al; “Tumor Necrosis Factor-α in Diabetic Plasma Increases the Activity of Core 2 GLcNAc-T and Adherence of Human Leukocytes to Retinal Endothelial Cells”;Diabetes, vol. 53, 2968-2976 (2004).
Brockhausen, I., et al; “Biosynthesis of O-Glycans in Leukocytes from Normal Donors and from Patients with Leukemia: Increase in O-Glycan Core 2 UDP-GlcNAc:Galβ1-3GalNAc-R (GlcNAc to GalNAc)β1(1-6)-N-Acetylglucosaminyltransferase in Leukemic Cells”;Cancer Research; 51, 1257-1263 (1991).
Buerke, Michael, et al; “Sialyl Lewisx—Containing Oligosaccharide Attenuates Myocardial Reperfusion Injury in Cats”;J. Clin. Invest.; vol. 93, 1140-1148 (1994).
Beum, P. V. and Cheng, Pi-W.; “Biosynthesis and Function of β1,6 Branched Mucin-Type Glycans”;The Molecular Immunology of Complex Carbohydrates-2(2001).
Beum, P. V., et al; “Mucin biosynthesis: upregulation of core 2 β1,6N-acetylglucosaminyltransferase by retinoic acid and Th2 cytokines in a human airway epithelial cell line”;Am J. Physiol Lung Cell Mol Physiol.; 288: L116-L124 (2005).
Beum, P. V., et al; “Mucin Biosynthesis Epidermal Growth Factor Downregulates Core 2 Enzymes in a Human Airway Adenocarcinoma Cell Line”;Am. J. Respir. Cell Mol. Biol.; vol. 29, 48-56 (2003).
Celie, J.W.A.M, et al; “Identification of L-Selectin Binding Heparan Sulfates Attached to Collagen Type XVIII”;J. Biol Chem.; 280(29); 26965-73; Epub (2005).
Dennis, James W.; “Glyco-Forum Section; Core 2 GlcNAc-Transferase and polylactosamine expression inO-glycans”,Glycobiology; vol. 3, No. 2, pp. 91-96 (1993).
Dube, Danielle H. et al, “Glycans in Cancer and Inflammation—Potential for Therapeutics and Diagnostics”,Nature Reviews, vol. 4, No. 6, 477-288 (2005).
Duan L-L. et al; “Regulation of Metastasis-Suppressive Gene Nm23-H1 on Glycosy-transferases Involved in the Synthesis of Sialy Lewis Antigens”;J. Cell. Biochem.; 94:1248-1257 (2005).
Fox, R.I., et al; “A Novel Cell Surface Antigen (T305) Found in Increased Fequency on Acute Leukemia Cells and in Autommune Disease States”;J. Immunol. vol. 131, No. 2, 761-767 (1983).
Foxall, C. et al; “The Three Members of the Selectin Receptor Family Recognize a Common Carbohydrate Epitope, the Sialyl LewisxOligosaccharide”;J. Cell Biol.; vol. 117, 895-902 (1992).
Fugang P. et al.; “Post Translational Modifications of Recombinant P-selectin Glycoprotein Ligand-1 Required for Binding to P and E-selectin”;J. Biol. Chem.; vol. 271, No. 6, 3255-3264 (1996).
Fujita, M. et al; “Pulmonary hypertension in TNF-α-overexpressing mice is associated with decreased VEGF gene expression”;J. Applied Physiol; vol. 93, 2162-2170 (2002).
Goss, P. E. et al; “Inhibitors of Carbohydrate Processing: A New Class of Anticancer Agents1,2”;Clin. Cancer Res.; vol. 1, 935-944 (1995).
Maaheimo,Hannu et al, “Synthesis of a divalent sialyl Lewis x O-glycan, a potent inhibitor of lymphocyte-endothelium adhesion”;Eur J. Biochem; 234, 616-625 (1995).
Hiraoka, N. et al; “Core 2 Branching β1,6-N-Acetylglucosaminyltransferase and High Endothelial Venule-restricted Sulfotransferase Collaboratively Control Lymphocyte Ho
BTG International Limited
Martin Paul C.
Nixon & Vanderhye
Prouty Rebecca E.
LandOfFree
Core 2 β(1,6)-acetylglycosaminyltransferase as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Core 2 β(1,6)-acetylglycosaminyltransferase as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Core 2 β(1,6)-acetylglycosaminyltransferase as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4184245